Biotech, Food & Drug

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Dec
19
2011
Taking a Cue From Brazil's Sustainable Development Practices Past and Present Sheppard, Mullin, Richter & Hampton LLP
Dec
19
2011
Sino-U.S. Trade: Increasing Government Intervention Leads to Added Friction Greenberg Traurig, LLP
Dec
16
2011
Lake Michigan Winds Being Measured Varnum LLP
Dec
12
2011
FDA Announces Proposals for Biosimilars User Fees and Performance Review Goals Sheppard, Mullin, Richter & Hampton LLP
Nov
19
2011
Inexperience and Unproven Products: The Risks of Sustainable Construction Risk and Insurance Management Society, Inc. (RIMS)
Oct
31
2011
GOP to Subpoena White House over Solyndra Center for Public Integrity
Oct
27
2011
Is an Isolated DNA Patentable? Hunton Andrews Kurth
Oct
11
2011
Solar Energy Is Viable For Office Properties Sills Cummis & Gross P.C.
Oct
10
2011
Six Important Strategies To Reduce The Royalty Burden For A Pharmaceutical Product Sills Cummis & Gross P.C.
Oct
6
2011
California AB 32's Cap-And-Trade Program Developments Sheppard, Mullin, Richter & Hampton LLP
Oct
4
2011
Donor Warned Obama that Solyndra 'could haunt him' Center for Public Integrity
Oct
1
2011
Solyndra Executives Refusing to Answer Bankruptcy Questions Center for Public Integrity
Sep
20
2011
A Liquid Layer Solution for the Grid U.S. Department of Energy
Sep
19
2011
The Truth about Clean Energy Jobs U.S. Department of Energy
Sep
16
2011
GOP Demands Investigation into LightSquared Contacts with White House Center for Public Integrity
Sep
16
2011
Obama Administration Withdraws Draft Ozone Ambient Air Quality Standards and Reinstates 2008 Standards Morgan, Lewis & Bockius LLP
Sep
11
2011
Solyndra Investigation Expands as Agents Visit Executives’ Homes Center for Public Integrity
Sep
8
2011
Congressional Hearing to Focus on Obama Administration Loan to Failed Energy Firm Center for Public Integrity
Sep
1
2011
Obama-backed Solar Firm Collapses After A Big Federal Loan Guarantee Center for Public Integrity
Sep
1
2011
Can Genes Be Patented? McDermott Will & Emery
Sep
1
2011
IHS Report Says EPA Greenhouse Gas Formula Flawed Greenberg Traurig, LLP
Aug
22
2011
Foreign Responses To Climate Change May Impose Carbon Footprint On US Companies Greenberg Traurig, LLP
Aug
18
2011
Department of Energy Awards Nearly $7 Million to Advance Fuel Cell and Hydrogen Storage Systems Research U.S. Department of Energy
Aug
17
2011
Green Groups Challenge EPA's Air Pollution Exemption for Biomass Power Plants Center for Public Integrity
Aug
12
2011
EPA Announces Top Contenders in Energy Star National Building Competition / In the first six months of the competition, participants saved more than $3.7 million on utility bills U.S. Environmental Protection Agency
Aug
10
2011
Commercial Biopharma in Wisconsin: What Next? Michael Best & Friedrich LLP
Aug
10
2011
White House Announces First Ever Oil Savings Standards for Heavy Duty Trucks, Buses/Saving $50 billion in fuel costs and over 500 million barrels of oil U.S. Environmental Protection Agency
Aug
9
2011
Federal Circuit Issues Opinion on Gene Patents in AMP et al v. Myriad Genetics, et al. McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins